Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.41 |
| ▸ | RELA | Q04206 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377655 | 0.90 | KDM1A (0.40) | BTKKDM1ANFKB1NFKB2RELA | |
| SCHEMBL3384745 | 0.89 | KDM1A (0.39) | BTKKDM1ANFKB1NFKB2RELA | |
| SCHEMBL14837522 | 0.88 | BTK (0.51) | BTKKDM1ANFKB1NFKB2RELA | |
| SCHEMBL19931998 | 0.87 | KDM1A (0.40) | BTKKDM1ANFKB1NFKB2RELA | |
| SCHEMBL16510329 | 0.86 | BTK (0.40) | BTKKDM1ANFKB1NFKB2RELA | |
| SCHEMBL5722405 | 0.86 | BTK (0.40) | BTKKDM1ANFKB1NFKB2RELA | |
| SCHEMBL8067532 | 0.84 | BTK (0.43) | BTKKDM1ANFKB1NFKB2RELA | |
| SCHEMBL8067531 | 0.84 | BTK (0.43) | BTKKDM1ANFKB1NFKB2RELA | |
| SCHEMBL3375340 | 0.84 | BTK (0.43) | BTKKDM1ANFKB1NFKB2RELA | |
| SCHEMBL13564070 | 0.84 | BTK (0.43) | BTKKDM1ANFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119219608-A | Polycyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-7488848-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070021353-A1 | Alpha ketoamide compounds as cysteine protease inhibitors | APPLERA CORPORATION (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021353-A1 | Alpha ketoamide compounds as cysteine protease inhibitors | CTSS, CTSF, CTSB | BTK 3351/4885KDM1A 865/4885NFKB1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.